A video-based automated driving simulator for automotive UI prototyping, UX and behaviour research

The lack of automated cars above SAE level 3 raises challenges for conducting User Experience Design (UXD) and behaviour research for automated driving. User-centred methods are critical to ensuring a human-friendly progress of vehicle automation. This work introduces the Immersive Video-based Automated Driving (IVAD) Simulator. It uses carefully recorded 180/360° videos that are played back in a driving simulator. This provides immersive driving experiences in visually realistic and familiar environments. This paper reports learnings from an iterative development of IVAD, and findings of two user studies: One simulator study (N=15) focused on the immersive experience; and one VR study (N=16) focused on rapid prototyping and the evaluation of Augmented Reality (AR) concepts. Overall, we found the method to be a useful, versatile and low budget UXD tool with a high level of immersion that is uniquely aided by the familiarity of the environment. IVAD's limitations and future improvements are discussed in relation to research applications within AutoUI

Self-Interruptions of Non-Driving Related Tasks in Automated Vehicles: Mobile vs Head-Up Display

Automated driving raises new human factors challenges. There is a paradox that allows drivers to perform non-driving related tasks (NDRTs), while benefiting from a driver who regularly attends to the driving task. Systems that aim to better manage a driver's attention, encouraging task switching and interleaving, may help address this paradox. However, a better understanding of how drivers self-interrupt while engaging in NDRTs is required to inform such systems. This paper presents a counterbalanced within-subject simulator study with N=42 participants experiencing automated driving in a familiar driving environment. Participants chose a TV show to watch on a HUD and mobile display during two 15min drives on the same route. Eye and head tracking data revealed more self-interruptions in the HUD condition, suggesting a higher likelihood of a higher situation awareness. Our results may benefit the design of future attention management systems by informing the visual and temporal integration of the driving and non-driving related task

Variability in the Performance of Nuclear Matrix Protein 22 for the Detection of Bladder Cancer

PURPOSE: We assessed variability in the diagnostic performance of NMP22 for detecting recurrence and progression in patients with Ta, T1, and/or CIS transitional cell carcinoma of the bladder in a large international cohort. MATERIALS AND METHODS: NMP22 voided urine levels were measured in 2,871 patients who underwent office cystoscopy for monitoring previous stage Ta, T1 and/or CIS transitional cell carcinoma at 12 participating institutions. RESULTS: Patient characteristics varied considerably among institutions. Overall 1,045 patients (36.4%) had recurrent transitional cell carcinoma (range across institutions 13.6% to 54.3%). Median NMP22 was 5.5 U/ml (range across institutions 2.5 to 18.8). Of the patients 33.5% had grade III tumors (range across institutions 20.6% to 54.0%) and 22.4% had muscle invasive tumors (range across institutions 3.2% to 38.2%). Area under the ROC curve for bladder TCC detection was 0.735 (95% CI 0.715 to 0.755, range across institutions 0.676 to 0.889). The manufacturer recommended cutoff of 10 U/ml detected 57% of cases with a 19% false-positive rate. AUC for grade III and stage T2 or greater disease was 0.806 (95% CI 0.780 to 831) and 0.864 (95% CI 0.839 to 0.890), respectively. For each NMP22 cutoff NMP22 had higher sensitivity for detecting grade III and stage T2 or greater bladder transitional cell carcinoma than for detecting any cancer. No optimal cutoffs for detecting any or aggressive bladder transitional cell carcinoma could be derived based on NMP22 values. CONCLUSIONS: There is a substantial degree of heterogeneity in the diagnostic performance of NMP22 applied to populations from different institutions. There is no clearly defined NMP22 cutoff but there is a continuum of risk for recurrence and progression